The Peptide Addict Intel is our weekly newsletter. One email, Sunday mornings. No product promotions. No affiliate dumps. No "12 peptides you MUST try." Just what actually changed in the peptide market this week, what it means, and what's worth watching.
What's in it
Every issue follows the same structure:
- The one thing that mattered most this week — the single most important development, named and contextualized.
- Study of the week — one research paper worth knowing about, with what it proves and what it doesn't.
- Regulatory watch — FDA, compounding, enforcement, or access changes.
- Vendor or market shift — changes in the vendor landscape or the commercial dynamics.
- One myth we need to retire — a claim that keeps circulating despite the evidence.
- Best recent read — one article (from us or elsewhere) worth your time.
- What we're watching next — the questions we're tracking for next week.
Who it's for
Smart adults who want peptide signal without peptide noise. If you're a:
- Health-optimizer tired of bro-science
- Longevity or GLP-1 curious reader who wants clarity
- Fitness professional whose clients are asking about peptides
- Clinician keeping up with what patients are buying
- Journalist, researcher, or investor tracking the category
...this is written for you.
What it's not
- Not a vendor promo stream
- Not a coaching funnel
- Not "secret stacks" or "exclusive protocols"
- Not affiliate marketing disguised as editorial
Sign up
Related
- Editorial Policy — the rules the newsletter follows.
- About The Peptide Addict — who we are.
- Beginner's Guide to Peptides — the foundational reading if you're new.